Short answer
HAEMONETICS CORP (HAE) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 fiscal 2026 results covered quarter ended June 27, 2026.
HAEMONETICS CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 fiscal 2026 results covered quarter ended June 27, 2026
- Press release furnished as Exhibit 99.1, containing the financial results and management commentary
- August 6, 2026 issuance provides investors the company’s latest quarterly performance update
Item EX-99.1 · Exhibit EX-99.1
- Q1 FY27 revenue $339.4M, up 5.6%, with organic growth 5.9% across Apheresis and MedSurg
- Adjusted EPS $1.14, up 3.6%, despite adjusted operating margin declining 70 basis points to 23.4%
- Plasma growth 8.2% organically and Blood Management Technologies growth 8.1%, supporting portfolio momentum
- FY27 reported revenue guidance raised to 5–8% from 4–7%; organic growth raised to 4–7% from 3–6%
- Operating cash flow rose to $52.3M and free cash flow to $39.1M, while debt repayments reduced cash to $223.4M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other HAEMONETICS CORP 8-K filings
Get the next HAE 8-K as it lands
Follow HAE for push alerts, or ask the research agent what this filing means.